Relmada Therapeutics
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -18,818 | -22,987 | -26,829 | -22,061 |
EBIT | -37,637 | -45,975 | -53,658 | -44,754 |
Net Income | -17,768 | -21,828 | -25,165 | -22,002 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -13,263 | -13,036 | -10,249 | -11,631 |
Cash | 2,086 | 1,335 | 4,091 | 6,698 |
Basic Shares | 30,174 | 30,132 | 30,099 | 30,099 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -1 | -3 | ||
EBITDA | 4,910 | -156,443 | -124,454 | -60,817 |
EBIT | -98,791 | -156,445 | -124,456 | -60,821 |
Net Income | -98,791 | -157,043 | -125,751 | -59,456 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -39,047 | |||
Free Cash Flow | -51,659 | -103,801 | -91,873 | -27,808 |
Cash | 4,091 | 5,395 | 44,443 | 2,495 |
Basic Shares | 30,099 | 29,628 | 17,552 | 15,594 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$0.59 |
2024-03-31 | -$0.72 |
2023-12-31 | -$0.84 |
2023-09-30 | -$0.73 |
